Cargando…

Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control

Alemtuzumab is a monoclonal antibody targeting CD52 on the surface of immune cells, approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). The purpose of this study was to analyze the repopulation of peripheral lymphocytes following alemtuzumab-induced lymphocyte depleti...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Essen, Marina Rode, Chow, Helene Højsgaard, Holm Hansen, Rikke, Buhelt, Sophie, Sellebjerg, Finn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512074/ https://www.ncbi.nlm.nih.gov/pubmed/37744364 http://dx.doi.org/10.3389/fimmu.2023.1249201

Ejemplares similares

Intrathecal CD8(+)CD20(+) T Cells in Primary Progressive Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis
por: Holm Hansen, Rikke, et al.
Publicado: (2022)

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial
por: Højsgaard Chow, Helene, et al.
Publicado: (2021)

Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls
por: Buhelt, Sophie, et al.
Publicado: (2019)

Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2022)

IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2Rα in CD8(+) T Cells
por: Buhelt, Sophie, et al.
Publicado: (2021)

Pulsed immune reconstitution therapy in multiple sclerosis
por: Sorensen, Per Soelberg, et al.
Publicado: (2019)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Progressive multiple sclerosis, cognitive function, and quality of life
por: Højsgaard Chow, Helene, et al.
Publicado: (2018)

Proinflammatory Effects of Diesel Exhaust Nanoparticles on Scleroderma Skin Cells
por: Mastrofrancesco, A., et al.
Publicado: (2014)

Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment
por: McRitchie, Bayley R., et al.
Publicado: (2022)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial
por: Hansen, Julie Schjødtz, et al.
Publicado: (2023)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Salvage therapies of autoimmune hepatitis limit proinflammatory immune cells while sparing regulatory T cells
por: Derben, Finn C., et al.
Publicado: (2023)

Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
por: Kim, Yeseul, et al.
Publicado: (2018)

Pathogen regulatory RNA usage enables chronic infections, T-cell exhaustion and accelerated T-cell exhaustion
por: Roe, Kevin
Publicado: (2023)

Role of Regulatory and Proinflammatory T-Cell Populations in Allergic Diseases
por: Orihara, Kanami, et al.
Publicado: (2008)

Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness
por: Bouvy, Anne P., et al.
Publicado: (2016)

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection
por: Penaloza-MacMaster, Pablo, et al.
Publicado: (2014)

Identification of informative features for predicting proinflammatory potentials of engine exhausts
por: Wang, Chia-Chi, et al.
Publicado: (2017)

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies
por: Cooles, Faye A. H., et al.
Publicado: (2016)

Alemtuzumab-induced elimination of HIV-1-infected immune cells
por: Ruxrungtham, Kiat, et al.
Publicado: (2016)

Dynamic chromatin regulatory landscape of human CAR T cell exhaustion
por: Gennert, David G., et al.
Publicado: (2021)

Transcriptional regulatory network for the establishment of CD8(+) T cell exhaustion
por: Seo, Wooseok, et al.
Publicado: (2021)

Exhausted and Apoptotic BALF T Cells in Proinflammatory Airway Milieu at Acute Phase of Severe Mycoplasma Pneumoniae Pneumonia in Children
por: Chen, Xi, et al.
Publicado: (2022)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C
por: Barili, Valeria, et al.
Publicado: (2021)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
por: Meeuse, Jan J., et al.
Publicado: (2007)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle
por: Poupiot, Jérôme, et al.
Publicado: (2019)

Inflammatory vaginitis associated with long-term rituximab treatment in a patient with multiple sclerosis
por: Filikci, Zuhal, et al.
Publicado: (2022)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ft9k3lf0ansqg705dgoc45nc0q